HeartBeam Receives FDA Clearance for Acute Myocardial Infarction Assessment Technology

HeartBeam (BEAT) announced that the FDA cleared its technology for assessing acute myocardial infarction. The portable ECG solution is designed to help diagnose acute cardiac events outside traditional hospital settings and supports the company’s strategy to expand remote cardiac monitoring. The article did not report financial figures or a stock-price reaction.